Last updated on April 2019

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Brief description of study

The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.

Clinical Study Identifier: NCT03618550

Find a site near you

Start Over

Memorial Sloan Kettering Nassau

Uniondale, NY United States
  Connect »

Memorial Sloan Kettering @ Rockville

Rockville Centre, NY United States
  Connect »